Michael D. Pak

Array ( [id] => 18879515 [patent_doc_number] => 20240002884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => ONCOLYTIC VIRUS VECTOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/349983 [patent_app_country] => US [patent_app_date] => 2023-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18349983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861972 [patent_doc_number] => 20230416408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => Compositions and Methods for Targeting Stromal Cells for the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 18/336530 [patent_app_country] => US [patent_app_date] => 2023-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18336530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955171 [patent_doc_number] => 20240043498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => GLYCOPROTEIN HORMONE RECEPTOR MUTATIONS [patent_app_type] => utility [patent_app_number] => 18/336792 [patent_app_country] => US [patent_app_date] => 2023-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 243 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18336792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18915796 [patent_doc_number] => 11878062 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Multimeric T-cell modulatory polypeptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/334911 [patent_app_country] => US [patent_app_date] => 2023-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 108 [patent_figures_cnt] => 137 [patent_no_of_words] => 80352 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879430 [patent_doc_number] => 20240002799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => METHOD FOR GENERATING HUMAN DENDRITIC CELLS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/313852 [patent_app_country] => US [patent_app_date] => 2023-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18313852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18567108 [patent_doc_number] => 20230257437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => FUSION MOLECULES AND IL-15 VARIANTS [patent_app_type] => utility [patent_app_number] => 18/305965 [patent_app_country] => US [patent_app_date] => 2023-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18305965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18753988 [patent_doc_number] => 20230357345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => Glycoprotein Hormone Long-Acting Superagonists [patent_app_type] => utility [patent_app_number] => 18/296005 [patent_app_country] => US [patent_app_date] => 2023-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18529945 [patent_doc_number] => 20230235012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 18/172258 [patent_app_country] => US [patent_app_date] => 2023-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 120000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18172258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511611 [patent_doc_number] => 20230227780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS [patent_app_type] => utility [patent_app_number] => 18/157618 [patent_app_country] => US [patent_app_date] => 2023-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18157618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19159020 [patent_doc_number] => 20240151727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => DIAGNOSTIC ALGORITHMS FOR DETERMINING AND TREATING CLINICALLY SIGNIFICANT PROSTATE CANCER BASED ON SIALYLATED AND FUCOSYLATED PROSTATE SPECIFIC ANTIGEN [patent_app_type] => utility [patent_app_number] => 18/098435 [patent_app_country] => US [patent_app_date] => 2023-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18098435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879467 [patent_doc_number] => 20240002836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY [patent_app_type] => utility [patent_app_number] => 18/156138 [patent_app_country] => US [patent_app_date] => 2023-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511378 [patent_doc_number] => 20230227524 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => POLYPEPTIDE AND METHOD OF PRODUCING IMP USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/154296 [patent_app_country] => US [patent_app_date] => 2023-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18531098 [patent_doc_number] => 20230236169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => NANOPLASMONIC BIOSENSOR FOR DETECTING AUTOPHAGY MARKER WITH HIGH SENSITIVITY, AND METHOD OF DETECTING AUTOPHAGY MARKER AND METHOD OF SCREENING DRUG CANDIDATE USING SAME [patent_app_type] => utility [patent_app_number] => 18/095107 [patent_app_country] => US [patent_app_date] => 2023-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18095107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451586 [patent_doc_number] => 20230192864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors [patent_app_type] => utility [patent_app_number] => 18/067085 [patent_app_country] => US [patent_app_date] => 2022-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18470293 [patent_doc_number] => 20230204578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => RECEPTOR TYROSINE KINASE BIOMARKERS [patent_app_type] => utility [patent_app_number] => 18/079119 [patent_app_country] => US [patent_app_date] => 2022-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18079119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18239415 [patent_doc_number] => 20230071726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => USE OF MYOG GENE AS TARGET IN PREPARATION OF DRUG FOR TREATING CARDIOMYOCYTE APOPTOSIS-ASSOCIATED CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 18/053769 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20593586 [patent_doc_number] => 12577288 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Methods and compositions relating to chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 18/053432 [patent_app_country] => US [patent_app_date] => 2022-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 38 [patent_no_of_words] => 35431 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18239010 [patent_doc_number] => 20230071321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => TOOLS AND METHODS FOR EXPRESSION OF MEMBRANE PROTEINS [patent_app_type] => utility [patent_app_number] => 18/048946 [patent_app_country] => US [patent_app_date] => 2022-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18658021 [patent_doc_number] => 20230303985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => FUSION PROTEINS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 18/046131 [patent_app_country] => US [patent_app_date] => 2022-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41823 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18530271 [patent_doc_number] => 20230235341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => ANTI-ANGIOGENIC GENE THERAPY WITH SOLUBLE VEGF RECEPTORS -1, -2 AND -3 TOGETHER WITH PACLITAXEL PROLONGS SURVIVAL OF MICE WITH HUMAN OVARIAN CARCINOMA [patent_app_type] => utility [patent_app_number] => 17/955417 [patent_app_country] => US [patent_app_date] => 2022-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17955417 [rel_patent_id] =>[rel_patent_doc_number] =>)